Duncan Alexander Hay

This inventor holds 10 USPTO granted patents and 4 published patent applications and 5 EPO patents. Top assignees: Enterprise Therapeutics Limited, Tmem16a Limited. Active years: 2020-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Duncan Alexander Hay. Retrieved from https://idiyas.com/inventor/duncan-alexander-hay

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 4)

% Patents Active = 100.0

EPO Patents = 5 (Patent Applications = 10)

Average Co-Inventor Count = 5.4

ph-index = 1

Forward Citations = 10(Granted Patents)

Location History:

Wallingford, GB (2022)
Abingdon, GB (2020 - 2024)

Company Filing History:

6 out of 6

Enterprise Therapeutics Limited

Years Active: 2020-2026

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12552770 - Compounds for treating respiratory disease (2026-02-17),

2. 12415793 - Modulators of TMEM16A for treating respiratory disease (2025-09-16),

3. 12377105 - Compounds (2025-08-05),

4. 12371436 - Substituted benzodiazoliums as ENaC inhibitors (2025-07-29),

5. 12037336 - Compounds with activity as inhibitors of the epithelial sodium channel (ENaC) (2024-07-16),

6. 11739094 - Substituted benzodiazoliums as ENaC inhibitors (2023-08-29),

7. 11370778 - Bis(pentahydroxyhexyl)amino substituted 2-{[(3-amino-pyrazin-2-yl)formamido]methyl}-1H-1,3-benzodiazol-3-ium derivatives as ENaC inhibitors for treating respiratory diseases (2022-06-28),

8. 11364246 - Compounds (2022-06-21),

9. 10941149 - Substituted benzodiazoliums as ENaC inhibitors (2021-03-09),

10. 10759785 - Compounds (2020-09-01),

Title: The Innovative Mind of Duncan Alexander Hay

Introduction

Duncan Alexander Hay is a renowned inventor based in Abingdon, GB. With an impressive portfolio of five patents, he has significantly contributed to the field of medicinal chemistry, particularly in developing inhibitors for the epithelial sodium channel (ENaC).

Latest Patents

His latest patents include innovative compounds demonstrated to act as inhibitors of the epithelial sodium channel (ENaC). These compounds are characterized by the general formula (I), involving specific substitutions of R and X. The primary applications of these inventions are in the treatment or prevention of various respiratory diseases and conditions, as well as skin and ocular conditions.

Another noteworthy patent by Hay focuses on substituted benzodiazoliums, which also serve as ENaC inhibitors. This further underscores his commitment to addressing significant health issues through his innovative work.

Career Highlights

Duncan is currently associated with Enterprise Therapeutics Limited, a company dedicated to developing novel therapies for treating respiratory and other conditions. His efforts have been pivotal in advancing therapeutic strategies that target the epithelial sodium channel.

Collaborations

Throughout his career, Duncan has collaborated with notable professionals like Thomas Beauregard Schofield and Naomi Went. These collaborative efforts enhance the research capabilities and innovative potential of their respective projects.

Conclusion

Duncan Alexander Hay's contributions to the field of medicinal chemistry through his patents and collaborative work have established him as a prominent inventor. His ongoing efforts to develop ENaC inhibitors aim to provide novel solutions for patients suffering from various health conditions.

Profile summary based on public USPTO records.